{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:47:24Z","timestamp":1785912444632,"version":"3.56.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01822-0","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:13:17Z","timestamp":1785723197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-4753","authenticated-orcid":false,"given":"Ashleigh R.","family":"Poh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Pietrzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"De Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8132-9373","authenticated-orcid":false,"given":"Raffiela","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4189-9433","authenticated-orcid":false,"given":"Natalie","family":"Heriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Winship","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"1822_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel, E. M., Brand, R. E. & Goggins, M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 164, 752\u2013765 (2023).","journal-title":"Gastroenterology"},{"key":"1822_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop, T. F. et al. Pancreatic cancer. Lancet 405, 1182\u20131202 (2025).","journal-title":"Lancet"},{"key":"1822_CR3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.pan.2021.08.007","volume":"21","author":"B Thompson","year":"2021","unstructured":"Thompson, B. et al. A decision support tool for the detection of pancreatic cancer in general practice: a modified Delphi consensus. Pancreatology 21, 1476\u20131481 (2021).","journal-title":"Pancreatology"},{"key":"1822_CR4","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-14-0734","volume":"74","author":"AM Lennon","year":"2014","unstructured":"Lennon, A. M. et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res. 74, 3381\u20133389 (2014).","journal-title":"Cancer Res."},{"key":"1822_CR5","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1822_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jnci\/djaa004","volume":"112","author":"AL Blackford","year":"2020","unstructured":"Blackford, A. L. et al. Recent trends in the incidence and survival of stage 1A pancreatic cancer: a surveillance, epidemiology, and end results analysis. J. Natl. Cancer Inst. 112, 1162\u20131169 (2020).","journal-title":"J. Natl. Cancer Inst."},{"key":"1822_CR7","unstructured":"GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 4, 934\u2013947 (2019)."},{"key":"1822_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jama.2019.10232","volume":"322","author":"DK Owens","year":"2019","unstructured":"Owens, D. K. et al. Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement. JAMA 322, 438\u2013444 (2019).","journal-title":"JAMA"},{"key":"1822_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","volume":"69","author":"M Goggins","year":"2020","unstructured":"Goggins, M. et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69, 7\u201317 (2020). This international consensus guideline established widely adopted recommendations for surveillance eligibility, imaging strategies, and management of individuals at high risk of pancreatic cancer.","journal-title":"Gut"},{"key":"1822_CR10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1053\/j.gastro.2021.08.036","volume":"161","author":"P Consortium","year":"2021","unstructured":"Consortium, P. et al. Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium. Gastroenterology 161, 1751\u20131757 (2021). This international initiative proposed a coordinated framework for pancreatic cancer early detection and created a platform for prospective surveillance research across high-risk populations.","journal-title":"Gastroenterology"},{"key":"1822_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.gastro.2020.03.088","volume":"159","author":"HR Aslanian","year":"2020","unstructured":"Aslanian, H. R., Lee, J. H. & Canto, M. I. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology 159, 358\u2013362 (2020). This expert review provided evidence-based recommendations for pancreatic cancer surveillance in high-risk individuals and helped standardise clinical practice.","journal-title":"Gastroenterology"},{"key":"1822_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.gie.2021.12.001","volume":"95","author":"MS Sawhney","year":"2022","unstructured":"Sawhney, M. S. et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest. Endosc. 95, 817\u2013826 (2022).","journal-title":"Gastrointest. Endosc."},{"key":"1822_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","volume":"62","author":"MI Canto","year":"2013","unstructured":"Canto, M. I. et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62, 339\u2013347 (2013).","journal-title":"Gut"},{"key":"1822_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1053\/j.gastro.2018.05.035","volume":"155","author":"MI Canto","year":"2018","unstructured":"Canto, M. I. et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 155, 740\u2013751.e2 (2018).","journal-title":"Gastroenterology"},{"key":"1822_CR15","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1200\/JCO.22.00298","volume":"40","author":"M Dbouk","year":"2022","unstructured":"Dbouk, M. et al. The multicenter cancer of pancreas screening study: impact on stage and survival. J. Clin. Oncol. 40, 3257\u20133266 (2022). This landmark multicentre surveillance study demonstrated a substantial stage shift towards stage I disease and markedly improved survival among surveillance-detected pancreatic cancers.","journal-title":"J. Clin. Oncol."},{"key":"1822_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/gutjnl-2020-323611","volume":"71","author":"KA Overbeek","year":"2022","unstructured":"Overbeek, K. A. et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut 71, 1152\u20131160 (2022). This long-term surveillance cohort provided important evidence regarding surveillance yield, surgical outcomes, and the occurrence of interval cancers in high-risk individuals.","journal-title":"Gut"},{"key":"1822_CR17","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","volume":"34","author":"H Vasen","year":"2016","unstructured":"Vasen, H. et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J. Clin. Oncol. 34, 2010\u20132019 (2016). This prospective multicentre European cohort demonstrated the potential benefit of pancreatic cancer surveillance in high-risk individuals through earlier detection of resectable disease and improved survival outcomes.","journal-title":"J. Clin. Oncol."},{"key":"1822_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.6004\/jnccn.2023.7097","volume":"22","author":"G Zogopoulos","year":"2024","unstructured":"Zogopoulos, G. et al. The pancreatic cancer early detection (PRECEDE) study is a global effort to drive early detection: baseline imaging findings in high-risk individuals. J. Natl. Compr. Canc. Netw. 22, 158\u2013166 (2024). This large international cohort study described baseline imaging findings in high-risk individuals and demonstrated the feasibility of large-scale prospective surveillance programs.","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"1822_CR19","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu, C. et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 319, 2401\u20132409 (2018).","journal-title":"JAMA"},{"key":"1822_CR20","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","volume":"35","author":"K Shindo","year":"2017","unstructured":"Shindo, K. et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J. Clin. Oncol. 35, 3382\u20133390 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1822_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","volume":"21","author":"MB Yurgelun","year":"2019","unstructured":"Yurgelun, M. B. et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 21, 213\u2013223 (2019).","journal-title":"Genet Med."},{"key":"1822_CR22","doi-asserted-by":"crossref","unstructured":"Wagner, A. et al. The management of Peutz-Jeghers syndrome: European Hereditary Tumor Group (EHTG) Guideline. J. Clin. Med. 10, 473 (2021).","DOI":"10.3390\/jcm10030473"},{"key":"1822_CR23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1053\/gast.2000.20228","volume":"119","author":"FM Giardiello","year":"2000","unstructured":"Giardiello, F. M. et al. Very high risk of cancer in familial Peutz\u2013Jeghers syndrome. Gastroenterology 119, 1447\u20131453 (2000).","journal-title":"Gastroenterology"},{"key":"1822_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/jmedgenet-2012-101277","volume":"50","author":"SE Korsse","year":"2013","unstructured":"Korsse, S. E. et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J. Med. Genet. 50, 59\u201364 (2013).","journal-title":"J. Med. Genet."},{"key":"1822_CR25","doi-asserted-by":"publisher","first-page":"101783","DOI":"10.1016\/j.bpg.2021.101783","volume":"58\u201359","author":"DCF Klatte","year":"2022","unstructured":"Klatte, D. C. F. et al. Hereditary pancreatic cancer. Best. Pract. Res. Clin. Gastroenterol. 58\u201359, 101783 (2022). p.","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"1822_CR26","doi-asserted-by":"crossref","unstructured":"van Lier, M. G. F. et al. High cancer risk in Peutz\u2013Jeghers syndrome: a systematic review and surveillance recommendations. J. Am. College Gastroenterol. 105, 1258\u20131264 (2010).","DOI":"10.1038\/ajg.2009.725"},{"key":"1822_CR27","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","volume":"12","author":"N Hearle","year":"2006","unstructured":"Hearle, N. et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin. Cancer Res. 12, 3209\u20133215 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1822_CR28","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-08-0403","volume":"14","author":"FA de Snoo","year":"2008","unstructured":"de Snoo, F. A. et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin. Cancer Res. 14, 7151\u20137157 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1822_CR29","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1200\/JCO.22.00194","volume":"40","author":"DCF Klatte","year":"2022","unstructured":"Klatte, D. C. F. et al. Pancreatic cancer surveillance in carriers of a germline CDKN2A pathogenic variant: yield and outcomes of a 20-year prospective follow-up. J. Clin. Oncol. 40, 3267\u20133277 (2022). This 20-year prospective study of CDKN2A pathogenic variant carriers reported high resectability rates and improved survival following surveillance-detected pancreatic cancer.","journal-title":"J. Clin. Oncol."},{"key":"1822_CR30","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/ueg2.12662","volume":"12","author":"DCF Klatte","year":"2024","unstructured":"Klatte, D. C. F. et al. Pancreatic cancer surveillance: risk stratification of individuals with a germline CDKN2A pathogenic variant. U. Eur. Gastroenterol. J. 12, 1399\u20131403 (2024.","journal-title":"U. Eur. Gastroenterol. J."},{"key":"1822_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/gim.2014.153","volume":"17","author":"DB Zhen","year":"2015","unstructured":"Zhen, D. B. et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 17, 569\u2013577 (2015).","journal-title":"Genet Med."},{"key":"1822_CR32","doi-asserted-by":"crossref","unstructured":"Lee, Y. C., Lee, Y. L. & Li, C. Y. BRCA genes and related cancers: a meta-analysis from epidemiological cohort studies. Medicina 57, 905 (2021).","DOI":"10.3390\/medicina57090905"},{"key":"1822_CR33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li, S. et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J. Clin. Oncol. 40, 1529\u20131541 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1822_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jmg.2004.028829","volume":"42","author":"CJ van Asperen","year":"2005","unstructured":"van Asperen, C. J. et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 42, 711\u2013719 (2005).","journal-title":"J. Med. Genet."},{"key":"1822_CR35","doi-asserted-by":"publisher","first-page":"e35666","DOI":"10.1002\/cncr.35666","volume":"131","author":"BW Katona","year":"2025","unstructured":"Katona, B. W. et al. The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation. Cancer 131, e35666 (2025).","journal-title":"Cancer"},{"key":"1822_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s44276-025-00199-2","volume":"3","author":"EM Grindedal","year":"2025","unstructured":"Grindedal, E. M. et al. A prospective observational study of pancreatic cancer risk in men and women with pathogenic variants in BRCA1 or BRCA2. BJC Rep. 3, 83 (2025).","journal-title":"BJC Rep."},{"key":"1822_CR37","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J. Clin. Oncol. 38, 674\u2013685 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1822_CR38","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1399-0004.2010.01425.x","volume":"78","author":"EP Slater","year":"2010","unstructured":"Slater, E. P. et al. PALB2 mutations in European familial pancreatic cancer families. Clin. Genet. 78, 490\u2013494 (2010).","journal-title":"Clin. Genet."},{"key":"1822_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.1171202","volume":"324","author":"S Jones","year":"2009","unstructured":"Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).","journal-title":"Science"},{"key":"1822_CR40","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/j.gastro.2009.06.055","volume":"137","author":"MD Tischkowitz","year":"2009","unstructured":"Tischkowitz, M. D. et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137, 1183\u20131186 (2009).","journal-title":"Gastroenterology"},{"key":"1822_CR41","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1001\/jamaoncol.2021.3701","volume":"7","author":"FC Hsu","year":"2021","unstructured":"Hsu, F. C. et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene. JAMA Oncol. 7, 1664\u20131668 (2021).","journal-title":"JAMA Oncol."},{"key":"1822_CR42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10689-018-00117-1","volume":"18","author":"LH Biller","year":"2019","unstructured":"Biller, L. H., Syngal, S. & Yurgelun, M. B. Recent advances in Lynch syndrome. Fam. Cancer 18, 211\u2013219 (2019).","journal-title":"Fam. Cancer"},{"key":"1822_CR43","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","volume":"67","author":"P M\u00f8ller","year":"2018","unstructured":"M\u00f8ller, P. et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 67, 1306\u20131316 (2018).","journal-title":"Gut"},{"key":"1822_CR44","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1001\/jama.2009.1529","volume":"302","author":"F Kastrinos","year":"2009","unstructured":"Kastrinos, F. et al. Risk of pancreatic cancer in families with Lynch syndrome. Jama 302, 1790\u20131795 (2009).","journal-title":"Jama"},{"key":"1822_CR45","unstructured":"Bogdanski, A. M. et al. Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. eClinicalMedicine 91, 103755 (2026)."},{"key":"1822_CR46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jnci\/89.6.442","volume":"89","author":"AB Lowenfels","year":"1997","unstructured":"Lowenfels, A. B. et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Natl. Cancer Inst. 89, 442\u2013446 (1997).","journal-title":"J. Natl. Cancer Inst."},{"key":"1822_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/ng1096-141","volume":"14","author":"DC Whitcomb","year":"1996","unstructured":"Whitcomb, D. C. et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat. Genet. 14, 141\u2013145 (1996).","journal-title":"Nat. Genet."},{"key":"1822_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ebiom.2019.10.065","volume":"50","author":"M Suzuki","year":"2019","unstructured":"Suzuki, M. & Shimizu, T. Is SPINK1 gene mutation associated with development of pancreatic cancer? New insight from a large retrospective study. EBioMedicine 50, 5\u20136 (2019).","journal-title":"EBioMedicine"},{"key":"1822_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-025-00740-x","volume":"19","author":"Q-W Wang","year":"2025","unstructured":"Wang, Q.-W. et al. Genetics and clinical implications of SPINK1 in the pancreatitis continuum and pancreatic cancer. Hum. Genomics 19, 32 (2025).","journal-title":"Hum. Genomics"},{"key":"1822_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S1542-3565(04)00013-8","volume":"2","author":"N Howes","year":"2004","unstructured":"Howes, N. et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin. Gastroenterol. Hepatol. 2, 252\u2013261 (2004).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1822_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.dld.2011.08.003","volume":"44","author":"V Rebours","year":"2012","unstructured":"Rebours, V., L\u00e9vy, P. & Ruszniewski, P. An overview of hereditary pancreatitis. Dig. Liver Dis. 44, 8\u201315 (2012).","journal-title":"Dig. Liver Dis."},{"key":"1822_CR52","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1053\/j.seminoncol.2016.09.002","volume":"43","author":"GM Petersen","year":"2016","unstructured":"Petersen, G. M. Familial pancreatic cancer. Semin. Oncol. 43, 548\u2013553 (2016).","journal-title":"Semin. Oncol."},{"key":"1822_CR53","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-03-3823","volume":"64","author":"AP Klein","year":"2004","unstructured":"Klein, A. P. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 64, 2634\u20132638 (2004).","journal-title":"Cancer Res."},{"key":"1822_CR54","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/jnci\/djac167","volume":"114","author":"N Porter","year":"2022","unstructured":"Porter, N. et al. Risk of pancreatic cancer in the long-term prospective follow-up of familial pancreatic cancer kindreds. J. Natl. Cancer Inst. 114, 1681\u20131688 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"1822_CR55","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CMAR.S172421","volume":"12","author":"J Llach","year":"2020","unstructured":"Llach, J., Carballal, S. & Moreira, L. Familial pancreatic cancer: current perspectives. Cancer Manag Res. 12, 743\u2013758 (2020).","journal-title":"Cancer Manag Res."},{"key":"1822_CR56","doi-asserted-by":"publisher","first-page":"102079","DOI":"10.1016\/j.clinre.2023.102079","volume":"47","author":"L Del Nero","year":"2023","unstructured":"Del Nero, L. et al. Familial pancreatic cancer. Clin. Res. Hepatol. Gastroenterol. 47, 102079 (2023).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"1822_CR57","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.gtc.2022.06.006","volume":"51","author":"H Saba","year":"2022","unstructured":"Saba, H. & Goggins, M. Familial pancreatic cancer. Gastroenterol. Clin. North Am. 51, 561\u2013575 (2022).","journal-title":"Gastroenterol. Clin. North Am."},{"key":"1822_CR58","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.gastro.2005.05.007","volume":"129","author":"ST Chari","year":"2005","unstructured":"Chari, S. T. et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129, 504\u2013511 (2005).","journal-title":"Gastroenterology"},{"key":"1822_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.gastro.2007.10.040","volume":"134","author":"ST Chari","year":"2008","unstructured":"Chari, S. T. et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134, 95\u2013101 (2008).","journal-title":"Gastroenterology"},{"key":"1822_CR60","doi-asserted-by":"crossref","unstructured":"Moore, S. F. et al. Risk factors for pancreatic cancer in electronic health records: an umbrella review of systematic reviews and meta-analyses. eClinicalMedicine 85, 103297 (2025).","DOI":"10.1016\/j.eclinm.2025.103297"},{"key":"1822_CR61","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4239\/wjd.v11.i6.227","volume":"11","author":"M Wang","year":"2020","unstructured":"Wang, M., Yang, Y. & Liao, Z. Diabetes and cancer: epidemiological and biological links. World J. Diab. 11, 227\u2013238 (2020).","journal-title":"World J. Diab."},{"key":"1822_CR62","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/s41416-024-02693-9","volume":"130","author":"AK Clift","year":"2024","unstructured":"Clift, A. K. et al. Predicting the risk of pancreatic cancer in adults with new-onset diabetes: development and internal-external validation of a clinical risk prediction model. Br. J. Cancer 130, 1969\u20131978 (2024).","journal-title":"Br. J. Cancer"},{"key":"1822_CR63","doi-asserted-by":"publisher","first-page":"e70388","DOI":"10.1002\/cam4.70388","volume":"13","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Predicting pancreatic cancer in new-onset diabetes cohort using a novel model with integrated clinical and genetic indicators: a large-scale prospective cohort study. Cancer Med. 13, e70388 (2024).","journal-title":"Cancer Med."},{"key":"1822_CR64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/MEG.0000000000002052","volume":"34","author":"B Boursi","year":"2022","unstructured":"Boursi, B. et al. A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. Eur. J. Gastroenterol. Hepatol. 34, 33\u201338 (2022).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1822_CR65","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/jgh.16503","volume":"39","author":"S Ali","year":"2024","unstructured":"Ali, S. et al. Predicting the risk of pancreatic cancer in women with new-onset diabetes mellitus. J. Gastroenterol. Hepatol. 39, 1057\u20131064 (2024).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1822_CR66","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.gastro.2018.05.023","volume":"155","author":"A Sharma","year":"2018","unstructured":"Sharma, A. et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. Gastroenterology 155, 730\u2013739.e3 (2018).","journal-title":"Gastroenterology"},{"key":"1822_CR67","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2018.11.014","volume":"19","author":"G Zerboni","year":"2019","unstructured":"Zerboni, G. et al. Systematic review and meta-analysis: prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology 19, 2\u20139 (2019).","journal-title":"Pancreatology"},{"key":"1822_CR68","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pan.2023.12.009","volume":"24","author":"T Ohtsuka","year":"2024","unstructured":"Ohtsuka, T. et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 24, 255\u2013270 (2024).","journal-title":"Pancreatology"},{"key":"1822_CR69","doi-asserted-by":"publisher","first-page":"e2337799","DOI":"10.1001\/jamanetworkopen.2023.37799","volume":"6","author":"J de la Fuente","year":"2023","unstructured":"de la Fuente, J. et al. Long-term outcomes and risk of pancreatic cancer in intraductal papillary mucinous neoplasms. JAMA Netw. Open 6, e2337799 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1822_CR70","first-page":"788","volume":"108","author":"R Gr\u00fctzmann","year":"2011","unstructured":"Gr\u00fctzmann, R. et al. Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis. Dtsch. Arztebl. Int. 108, 788\u2013794 (2011).","journal-title":"Dtsch. Arztebl. Int."},{"key":"1822_CR71","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/jso.27414","volume":"128","author":"CM Lattimore","year":"2023","unstructured":"Lattimore, C. M. et al. Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features. J. Surg. Oncol. 128, 1087\u20131094 (2023).","journal-title":"J. Surg. Oncol."},{"key":"1822_CR72","unstructured":"Cancer Australia. Surveillance in people at high risk of pancreatic cancer: a guide for Australian primary care practitioners. Cancer Australia. 1\u201322, https:\/\/www.pancare.org.au\/files\/files\/content\/Surveillance%20in%20people%20at%20high%20risk%20of%20pancreatic%20cancer.pdf (2024)."},{"key":"1822_CR73","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.2023.41.4_suppl.689","volume":"41","author":"I Haimi","year":"2023","unstructured":"Haimi, I. et al. Pancreatic imaging findings from the PRECEDE study: a large high-risk heritable cohort for pancreatic cancer. J. Clin. Oncol. 41, 689\u2013689 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1822_CR74","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10689-024-00394-z","volume":"23","author":"B Boekestijn","year":"2024","unstructured":"Boekestijn, B. et al. Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions. Fam. Cancer 23, 295\u2013308 (2024).","journal-title":"Fam. Cancer"},{"key":"1822_CR75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10689-024-00380-5","volume":"23","author":"KA Overbeek","year":"2024","unstructured":"Overbeek, K. A., Cahen, D. L. & Bruno, M. J. The role of endoscopic ultrasound in the detection of pancreatic lesions in high-risk individuals. Fam. Cancer 23, 279\u2013293 (2024).","journal-title":"Fam. Cancer"},{"key":"1822_CR76","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2214\/AJR.22.27859","volume":"219","author":"C Huang","year":"2022","unstructured":"Huang, C. et al. Standardization of MRI screening and reporting in individuals with elevated risk of pancreatic ductal adenocarcinoma: consensus statement of the PRECEDE consortium. Am. J. Roentgenol. 219, 903\u2013914 (2022).","journal-title":"Am. J. Roentgenol."},{"key":"1822_CR77","doi-asserted-by":"crossref","unstructured":"Rogers, H. K. & Shah, S. L. Role of endoscopic ultrasound in pancreatic cancer diagnosis and management. Diagnostics 14, 1156 (2024)","DOI":"10.3390\/diagnostics14111156"},{"key":"1822_CR78","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.3748\/wjg.v18.i34.4659","volume":"18","author":"C Jenssen","year":"2012","unstructured":"Jenssen, C. et al. Diagnostic endoscopic ultrasonography: assessment of safety and prevention of complications. World J. Gastroenterol. 18, 4659\u20134676 (2012).","journal-title":"World J. Gastroenterol."},{"key":"1822_CR79","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.asjsur.2019.12.011","volume":"43","author":"G Tian","year":"2020","unstructured":"Tian, G. et al. Complication incidence of EUS-guided pancreas biopsy: a systematic review and meta-analysis of 11 thousand population from 78 cohort studies. Asian J. Surg. 43, 1049\u20131055 (2020).","journal-title":"Asian J. Surg."},{"key":"1822_CR80","doi-asserted-by":"crossref","unstructured":"Mizuide, M. et al. Complications of endoscopic ultrasound-guided fine needle aspiration: a narrative review. Diagnostics. 10, 964 (2020).","DOI":"10.3390\/diagnostics10110964"},{"key":"1822_CR81","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.pan.2022.07.015","volume":"22","author":"A Siegel","year":"2022","unstructured":"Siegel, A. et al. Concordance of EUS and MRI\/MRCP findings among high-risk individuals undergoing pancreatic cancer screening. Pancreatology 22, 951\u2013958 (2022).","journal-title":"Pancreatology"},{"key":"1822_CR82","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.3748\/wjg.v23.i17.3184","volume":"23","author":"C Du","year":"2017","unstructured":"Du, C. et al. Comparison of endoscopic ultrasound, computed tomography and magnetic resonance imaging in assessment of detailed structures of pancreatic cystic neoplasms. World J. Gastroenterol. 23, 3184\u20133192 (2017).","journal-title":"World J. Gastroenterol."},{"key":"1822_CR83","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1177\/2050640617752182","volume":"6","author":"M Signoretti","year":"2018","unstructured":"Signoretti, M. et al. Results of surveillance in individuals at high-risk of pancreatic cancer: a systematic review and meta-analysis. U. Eur. Gastroenterol. J. 6, 489\u2013499 (2018).","journal-title":"U. Eur. Gastroenterol. J."},{"key":"1822_CR84","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cgh.2018.04.065","volume":"17","author":"JE Corral","year":"2019","unstructured":"Corral, J. E. et al. Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: a meta-analysis of cohort studies. Clin. Gastroenterol. Hepatol. 17, 41\u201353 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1822_CR85","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/MCG.0b013e3181f42d69","volume":"45","author":"TB Gardner","year":"2011","unstructured":"Gardner, T. B. & Gordon, S. R. Interobserver agreement for pancreatic endoscopic ultrasonography determined by same day back-to-back examinations. J. Clin. Gastroenterol. 45, 542\u2013545 (2011).","journal-title":"J. Clin. Gastroenterol."},{"key":"1822_CR86","doi-asserted-by":"publisher","first-page":"175628482513590","DOI":"10.1177\/17562848251359006","volume":"18","author":"G Dell\u2019Anna","year":"2025","unstructured":"Dell\u2019Anna, G. et al. Current status and further directions of endoscopic ultrasound-directed transgastric ERCP and endoscopic ultrasound-directed transenteric ERCP in the management of pancreaticobiliary diseases in surgically altered anatomy: a comprehensive review. Ther. Adv. Gastroenterol. 18, 17562848251359006 (2025).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"1822_CR87","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/eus.eus_25_18","volume":"8","author":"IM Cazacu","year":"2019","unstructured":"Cazacu, I. M. et al. Psychological impact of pancreatic cancer screening by EUS or magnetic resonance imaging in high-risk individuals: a systematic review. Endosc. Ultrasound 8, 17\u201324 (2019).","journal-title":"Endosc. Ultrasound"},{"key":"1822_CR88","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.gastro.2012.01.005","volume":"142","author":"MI Canto","year":"2012","unstructured":"Canto, M. I. et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142, 796\u2013804 (2012).","journal-title":"Gastroenterology"},{"key":"1822_CR89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/SLA.0b013e31825ffbfb","volume":"257","author":"KE Poruk","year":"2013","unstructured":"Poruk, K. E. et al. Screening for pancreatic cancer: why, how, and who? Ann. Surg. 257, 17\u201326 (2013).","journal-title":"Ann. Surg."},{"key":"1822_CR90","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamaoncol.2024.1930","volume":"10","author":"AL Blackford","year":"2024","unstructured":"Blackford, A. L. et al. Pancreatic cancer surveillance and survival of high-risk individuals. JAMA Oncol. 10, 1087\u20131096 (2024). This matched analysis demonstrated that surveillance-detected pancreatic cancers were diagnosed at earlier stages and were associated with improved survival compared with population-based controls.","journal-title":"JAMA Oncol."},{"key":"1822_CR91","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.gastro.2021.10.014","volume":"162","author":"KA Overbeek","year":"2022","unstructured":"Overbeek, K. A. et al. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterology 162, 772\u2013785.e4 (2022).","journal-title":"Gastroenterology"},{"key":"1822_CR92","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/cancers16010086","volume":"16","author":"I Anez-Bruzual","year":"2024","unstructured":"Anez-Bruzual, I. et al. Assessment of the psychosocial impact of pancreatic cancer surveillance in high-risk individuals. Cancers 16, 86 (2024).","journal-title":"Cancers"},{"key":"1822_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10689-019-00147-3","volume":"19","author":"RS O\u2019Neill","year":"2020","unstructured":"O\u2019Neill, R. S. et al. Long-term positive psychological outcomes in an Australian pancreatic cancer screening program. Fam. Cancer 19, 23\u201335 (2020).","journal-title":"Fam. Cancer"},{"key":"1822_CR94","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10689-016-9930-4","volume":"16","author":"IC Konings","year":"2017","unstructured":"Konings, I. C. et al. Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Fam. Cancer 16, 143\u2013151 (2017).","journal-title":"Fam. Cancer"},{"key":"1822_CR95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/SLA.0000000000006094","volume":"279","author":"S Paiella","year":"2024","unstructured":"Paiella, S. et al. Surveillance of individuals at high risk of developing pancreatic cancer: a prevalence meta-analysis to estimate the rate of low-yield surgery. Ann. Surg. 279, 37\u201344 (2024).","journal-title":"Ann. Surg."},{"key":"1822_CR96","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s11605-019-04230-z","volume":"24","author":"MI Canto","year":"2020","unstructured":"Canto, M. I. et al. Surgical outcomes after pancreatic resection of screening-detected lesions in individuals at high risk for developing pancreatic cancer. J. Gastrointest. Surg. 24, 1101\u20131110 (2020).","journal-title":"J. Gastrointest. Surg."},{"key":"1822_CR97","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000485830","volume":"12","author":"C Mau","year":"2017","unstructured":"Mau, C. & Untch, M. Prophylactic surgery: for whom, when and how? Breast Care 12, 379\u2013384 (2017).","journal-title":"Breast Care"},{"key":"1822_CR98","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s11605-018-04084-x","volume":"23","author":"J Kusakabe","year":"2019","unstructured":"Kusakabe, J. et al. Long-term endocrine and exocrine insufficiency after pancreatectomy. J. Gastrointest. Surg. 23, 1604\u20131613 (2019).","journal-title":"J. Gastrointest. Surg."},{"key":"1822_CR99","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10689-024-00384-1","volume":"23","author":"E Maurer","year":"2024","unstructured":"Maurer, E. & Bartsch, D. K. Surgical aspects related to hereditary pancreatic cancer. Fam. Cancer 23, 341\u2013350 (2024).","journal-title":"Fam. Cancer"},{"key":"1822_CR100","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/2050640620945534","volume":"8","author":"L Scholten","year":"2020","unstructured":"Scholten, L. et al. Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables. U. Eur. Gastroenterol. J. 8, 865\u2013877 (2020).","journal-title":"U. Eur. Gastroenterol. J."},{"key":"1822_CR101","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ueg2.12360","volume":"11","author":"IS Ibrahim","year":"2023","unstructured":"Ibrahim, I. S. et al. Cost-effectiveness of pancreas surveillance: the CDKN2A-p16-Leiden cohort. U. Eur. Gastroenterol. J. 11, 163\u2013170 (2023). This modelling study suggested that pancreatic cancer surveillance may be cost-effective in individuals with very high inherited risk, particularly carriers of pathogenic CDKN2A variants.","journal-title":"U. Eur. Gastroenterol. J."},{"key":"1822_CR102","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/MPA.0000000000001268","volume":"48","author":"JE Corral","year":"2019","unstructured":"Corral, J. E. et al. Cost-effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis. Pancreas 48, 526\u2013536 (2019).","journal-title":"Pancreas"},{"key":"1822_CR103","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/OP.23.00495","volume":"20","author":"MLB Peters","year":"2024","unstructured":"Peters, M. L. B. et al. Cost-effectiveness analysis of screening for pancreatic cancer among high-risk populations. JCO Oncol. Pr. 20, 278\u2013290 (2024).","journal-title":"JCO Oncol. Pr."},{"key":"1822_CR104","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10689-024-00392-1","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer. Fam. Cancer 23, 351\u2013360 (2024).","journal-title":"Fam. Cancer"},{"key":"1822_CR105","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere, A. et al. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob. Health 11, e833\u2013e842 (2023).","journal-title":"Lancet Glob. Health"},{"key":"1822_CR106","first-page":"30","volume":"17","author":"T Dwarte","year":"2019","unstructured":"Dwarte, T. et al. Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program. Hered. Cancer Clin. Pr. 17, 30 (2019).","journal-title":"Hered. Cancer Clin. Pr."},{"key":"1822_CR107","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1002\/jgc4.70117","volume":"34","author":"GG Snyder","year":"2025","unstructured":"Snyder, G. G. et al. Assessment of barriers to pancreatic cancer surveillance in high-risk individuals. J. Genet Couns. 34, e70117 (2025).","journal-title":"J. Genet Couns."},{"key":"1822_CR108","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.pan.2025.05.002","volume":"25","author":"AA Lee","year":"2025","unstructured":"Lee, A. A. et al. Suboptimal adherence to surveillance in high-risk individuals for pancreatic cancer at a tertiary care academic center: Lessons from real-world surveillance patterns. Pancreatology 25, 540\u2013543 (2025).","journal-title":"Pancreatology"},{"key":"1822_CR109","unstructured":"Australian Institute of Health and Welfare. Cancer in Aboriginal & Torres Strait Islander People of Australia (AIHW, Canberra, 2018)."},{"key":"1822_CR110","first-page":"105","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J. Gastrointest. Oncol. 3, 105\u2013119 (2012).","journal-title":"J. Gastrointest. Oncol."},{"key":"1822_CR111","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/1097-0142(19910701)68:1<149::AID-CNCR2820680127>3.0.CO;2-9","volume":"68","author":"K Satake","year":"1991","unstructured":"Satake, K. et al. The possibility of diagnosing small pancreatic cancer (less than 4.0\u2009cm) by measuring various serum tumor markers. A retrospective study. Cancer 68, 149\u2013152 (1991).","journal-title":"Cancer"},{"key":"1822_CR112","doi-asserted-by":"crossref","unstructured":"Satake, K. & Takeuchi, T. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 9, 720\u2013724 (1994).","DOI":"10.1097\/00006676-199411000-00008"},{"key":"1822_CR113","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3390\/cancers2021107","volume":"2","author":"F R\u00fcckert","year":"2010","unstructured":"R\u00fcckert, F., Pilarsky, C. & Gr\u00fctzmann, R. Serum tumor markers in pancreatic cancer\u2014recent discoveries. Cancers 2, 1107\u20131124 (2010).","journal-title":"Cancers"},{"key":"1822_CR114","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1158\/2767-9764.CRC-22-0190","volume":"2","author":"LE Kane","year":"2022","unstructured":"Kane, L. E. et al. Diagnostic accuracy of blood-based biomarkers for pancreatic cancer: a systematic review and meta-analysis. Cancer Res. Commun. 2, 1229\u20131243 (2022).","journal-title":"Cancer Res. Commun."},{"key":"1822_CR115","doi-asserted-by":"publisher","first-page":"e00468","DOI":"10.14309\/ctg.0000000000000468","volume":"13","author":"RE Brand","year":"2022","unstructured":"Brand, R. E. et al. Detection of early-stage pancreatic ductal adenocarcinoma from blood samples: results of a multiplex biomarker signature validation study. Clin. Transl. Gastroenterol. 13, e00468 (2022).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"1822_CR116","doi-asserted-by":"publisher","first-page":"e2300445","DOI":"10.1200\/PO.23.00445","volume":"7","author":"BW Katona","year":"2023","unstructured":"Katona, B. W. et al. Outcomes of the IMMray PanCan-d test in high-risk individuals undergoing pancreatic surveillance: pragmatic data and lessons learned. JCO Precis Oncol. 7, e2300445 (2023).","journal-title":"JCO Precis Oncol."},{"key":"1822_CR117","unstructured":"Lennon, A. M. et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 369, eabb9601 (2020)."},{"key":"1822_CR118","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","volume":"402","author":"D Schrag","year":"2023","unstructured":"Schrag, D. et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 402, 1251\u20131260 (2023).","journal-title":"Lancet"},{"key":"1822_CR119","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jmoldx.2024.06.007","volume":"26","author":"S Chowdhury","year":"2024","unstructured":"Chowdhury, S. et al. Analytical validation of an early detection pancreatic cancer test using 5-hydroxymethylation signatures. J. Mol. Diagn. 26, 888\u2013896 (2024).","journal-title":"J. Mol. Diagn."},{"key":"1822_CR120","doi-asserted-by":"publisher","first-page":"108171","DOI":"10.1016\/j.compbiolchem.2024.108171","volume":"112","author":"S Samir","year":"2024","unstructured":"Samir, S. et al. Urinary biomarkers analysis as a diagnostic tool for early detection of pancreatic adenocarcinoma: molecular quantification approach. Comput. Biol. Chem. 112, 108171 (2024).","journal-title":"Comput. Biol. Chem."},{"key":"1822_CR121","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/bjs.10909","volume":"105","author":"SR Markar","year":"2018","unstructured":"Markar, S. R. et al. Profile of exhaled-breath volatile organic compounds to diagnose pancreatic cancer. Br. J. Surg. 105, 1493\u20131500 (2018).","journal-title":"Br. J. Surg."},{"key":"1822_CR122","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2021-324755","volume":"71","author":"E Kartal","year":"2022","unstructured":"Kartal, E. et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 71, 1359 (2022).","journal-title":"Gut"},{"key":"1822_CR123","doi-asserted-by":"publisher","first-page":"102110","DOI":"10.1016\/j.pmedr.2023.102110","volume":"31","author":"DCF Klatte","year":"2023","unstructured":"Klatte, D. C. F. et al. Identification of individuals at high-risk for pancreatic cancer using a digital patient-input tool combining family cancer history screening and new-onset diabetes. Prev. Med. Rep. 31, 102110 (2023).","journal-title":"Prev. Med. Rep."},{"key":"1822_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89607-8","volume":"15","author":"W Zhu","year":"2025","unstructured":"Zhu, W. et al. Identification of patients at risk for pancreatic cancer in a 3-year timeframe based on machine learning algorithms. Sci. Rep. 15, 11697 (2025).","journal-title":"Sci. Rep."},{"key":"1822_CR125","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1053\/j.gastro.2022.01.016","volume":"162","author":"S Sharma","year":"2022","unstructured":"Sharma, S. et al. Predicting pancreatic cancer in the UK Biobank cohort using polygenic risk scores and diabetes mellitus. Gastroenterology 162, 1665\u20131674.e2 (2022).","journal-title":"Gastroenterology"},{"key":"1822_CR126","doi-asserted-by":"crossref","unstructured":"Verras, G. I. et al. Utility of polygenic risk scores (PRSs) in predicting pancreatic cancer: a systematic review and meta-analysis of common-variant and mixed scores with insights into rare variant analysis. Cancers 17, 241 (2025).","DOI":"10.3390\/cancers17020241"},{"key":"1822_CR127","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.gastha.2023.05.008","volume":"2","author":"GS Dite","year":"2023","unstructured":"Dite, G. S. et al. Predicting 10-year risk of pancreatic cancer using a combined genetic and clinical model. Gastro. Hep. Adv. 2, 979\u2013989 (2023).","journal-title":"Gastro. Hep. Adv."},{"key":"1822_CR128","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MPA.0000000000001762","volume":"50","author":"B Kenner","year":"2021","unstructured":"Kenner, B. et al. Artificial intelligence and early detection of pancreatic cancer: 2020 summative review. Pancreas 50, 251\u2013279 (2021).","journal-title":"Pancreas"},{"key":"1822_CR129","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S1470-2045(25)00567-4","volume":"27","author":"N Alves","year":"2026","unstructured":"Alves, N. et al. Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study. Lancet Oncol. 27, 116\u2013124 (2026).","journal-title":"Lancet Oncol."},{"key":"1822_CR130","doi-asserted-by":"crossref","unstructured":"Tripathi, S. et al. From machine learning to patient outcomes: a comprehensive review of AI in pancreatic cancer. Diagnostics 14, 174 (2024).","DOI":"10.3390\/diagnostics14020174"},{"key":"1822_CR131","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/jnci\/92.15.1260","volume":"92","author":"A Borg","year":"2000","unstructured":"Borg, A. et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J. Natl. Cancer Inst. 92, 1260\u20131266 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"1822_CR132","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/ijc.25148","volume":"127","author":"EJ Jacobs","year":"2010","unstructured":"Jacobs, E. J. et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int. J. Cancer 127, 1421\u20131428 (2010).","journal-title":"Int. J. Cancer"},{"key":"1822_CR133","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/jso.27784","volume":"130","author":"WJ Kane","year":"2024","unstructured":"Kane, W. J. et al. Survival benefit associated with screening of patients at elevated risk for pancreatic cancer. J. Surg. Oncol. 130, 485\u2013492 (2024).","journal-title":"J. Surg. Oncol."},{"key":"1822_CR134","doi-asserted-by":"publisher","first-page":"739","DOI":"10.14309\/ajg.0000000000002546","volume":"119","author":"S Paiella","year":"2024","unstructured":"Paiella, S. et al. Outcomes of a 3-year prospective surveillance in individuals at high risk of pancreatic cancer. Am. J. Gastroenterol. 119, 739\u2013747 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"1822_CR135","doi-asserted-by":"publisher","first-page":"e00668","DOI":"10.14309\/ctg.0000000000000668","volume":"15","author":"G Rosner","year":"2024","unstructured":"Rosner, G. et al. Surveillance outcome and genetic findings in individuals at high risk of pancreatic cancer. Clin. Transl. Gastroenterol. 15, e00668 (2024).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"1822_CR136","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/ueg2.12631","volume":"12","author":"E Maurer","year":"2024","unstructured":"Maurer, E. et al. Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant-negative familial pancreatic cancer families. U. Eur. Gastroenterol. J. 12, 1211\u20131221 (2024).","journal-title":"U. Eur. Gastroenterol. J."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01822-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01822-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01822-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:03:04Z","timestamp":1785909784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01822-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01822-0","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"429"}}